The Latest Analyst Ratings for Day One Biopharmaceutical
Portfolio Pulse from Benzinga Insights
Day One Biopharmaceutical (NASDAQ:DAWN) has received 5 analyst ratings in the last quarter, with 4 being bullish and 1 somewhat bullish. The average price target is $42.0, representing an upside from the current price of $14.72. This average price target is a 33.33% decrease from the previous average price target of $63.00.
September 12, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Day One Biopharmaceutical has received positive analyst ratings, which could potentially drive its stock price up.
Analyst ratings often influence investor sentiment and can drive stock prices. In this case, Day One Biopharmaceutical has received mostly bullish ratings, which could lead to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100